Activated CD4 T cells proliferate rapidly and remodel epigenetically before exiting the cell cycle and engaging acquired effector functions. Metabolic reprogramming from the naive state is required throughout these phases of activation 1 . In CD4 T cells, T-cell-receptor ligation-along with co-stimulatory and cytokine signals-induces a glycolytic anabolic program that is required for biomass generation, rapid proliferation and effector function 2 . CD4 T cell differentiation (proliferation and epigenetic remodelling) and function are orchestrated coordinately by signal transduction and transcriptional remodelling. However, it remains unclear whether these processes are regulated independently of one another by cellular biochemical composition. Here we demonstrate that distinct modes of mitochondrial metabolism support differentiation and effector functions of mouse T helper 1 (T H 1) cells by biochemically uncoupling these two processes. We find that the tricarboxylic acid cycle is required for the terminal effector function of T H 1 cells through succinate dehydrogenase (complex II), but that the activity of succinate dehydrogenase suppresses T H 1 cell proliferation and histone acetylation. By contrast, we show that complex I of the electron transport chain, the malate-aspartate shuttle and mitochondrial citrate export are required to maintain synthesis of aspartate, which is necessary for the proliferation of T helper cells. Furthermore, we find that mitochondrial citrate export and the malate-aspartate shuttle promote histone acetylation, and specifically regulate the expression of genes involved in T cell activation. Combining genetic, pharmacological and metabolomics approaches, we demonstrate that the differentiation and terminal effector functions of T helper cells are biochemically uncoupled. These findings support a model in which the malate-aspartate shuttle, mitochondrial citrate export and complex I supply the substrates needed for proliferation and epigenetic remodelling early during T cell activation, whereas complex II consumes the substrates of these pathways, which antagonizes differentiation and enforces terminal effector function. Our data suggest that transcriptional programming acts together with a parallel biochemical network to enforce cell state.
. CD4 T cell differentiation (proliferation and epigenetic remodelling) and function are orchestrated coordinately by signal transduction and transcriptional remodelling. However, it remains unclear whether these processes are regulated independently of one another by cellular biochemical composition. Here we demonstrate that distinct modes of mitochondrial metabolism support differentiation and effector functions of mouse T helper 1 (T H 1) cells by biochemically uncoupling these two processes. We find that the tricarboxylic acid cycle is required for the terminal effector function of T H 1 cells through succinate dehydrogenase (complex II), but that the activity of succinate dehydrogenase suppresses T H 1 cell proliferation and histone acetylation. By contrast, we show that complex I of the electron transport chain, the malate-aspartate shuttle and mitochondrial citrate export are required to maintain synthesis of aspartate, which is necessary for the proliferation of T helper cells. Furthermore, we find that mitochondrial citrate export and the malate-aspartate shuttle promote histone acetylation, and specifically regulate the expression of genes involved in T cell activation. Combining genetic, pharmacological and metabolomics approaches, we demonstrate that the differentiation and terminal effector functions of T helper cells are biochemically uncoupled. These findings support a model in which the malate-aspartate shuttle, mitochondrial citrate export and complex I supply the substrates needed for proliferation and epigenetic remodelling early during T cell activation, whereas complex II consumes the substrates of these pathways, which antagonizes differentiation and enforces terminal effector function. Our data suggest that transcriptional programming acts together with a parallel biochemical network to enforce cell state.
T cells require mitochondrial metabolism as they exit from the naive cell state to become activated, and as they return to being resting memory cells; however, the role of mitochondrial metabolism in the differentiation and function of effector T cells is less well-understood [3] [4] [5] . Metabolite tracing studies have revealed that, whereas activated T cells use glutamine for the anaplerosis of α-ketoglutarate, activated cells decrease the rate of pyruvate entry into the mitochondria in favour of lactate fermentation 5, 6 . Despite the decreased utilization of glucosederived carbon for mitochondrial metabolism, the tricarboxylic acid (TCA) cycle has previously been shown to contribute to IFNγ production by increasing cytosolic acetyl-CoA pools via mitochondrial citrate export 7 . Additionally, the TCA cycle can contribute to the electron transport chain (ETC) by generating NADH and succinate to fuel complex I and complex II, respectively. However, the role of the ETC in the later stages of T cell activation is poorly characterized. To test the contribution of the TCA cycle to the function of effector T cells, we treated cells cultured in T H 1 conditions with the TCA-cycle inhibitor sodium fluoroacetate 8 . We titrated sodium fluoroacetate or the glycolysis inhibitor 2-deoxy-d-glucose (2DG; an inhibitor of T H 1 cell activation, used as a positive control) at day 1 of T cell culture, and assayed cell proliferation at day 3 or the expression of the IfngKatushka reporter at day 5. Although 2DG was a more-potent inhibitor than sodium fluoroacetate at lower doses, both inhibitors impaired Ifng transcription (Fig. 1a) and T cell proliferation (Fig. 1b) in a dosedependent manner, which suggests that the activity of TCA-cycle enzymes is required for optimal T H 1 cell activation.
To evaluate which processes downstream of the TCA cycle contribute to the role of the TCA cycle in T-helper-cell proliferation and function, we treated T H 1 cells with inhibitors of the ETC overnight on day 2 (to evaluate proliferation) or overnight on day 4 (to evaluate cytokine production), and analysed cells the following day. Unlike impairing glycolysis with 2DG or the TCA cycle with sodium fluoroacetate, which resulted in a block of both proliferation and function, we observed a dichotomy in the role of the ETC in supporting each of these processes. Although the inhibition of complex II did not impair proliferation, blocking complex I and complex III resulted in a decrease in the number of divided cells; treatment with oligomycin displayed a modest but significant effect (Fig. 1c) . Importantly, viability was not affected upon acute inhibition of ETC complexes (Extended Data Fig. 1a) . Consistent with this observation, treatment with rotenone or antimycin A on day 2 resulted in cell-cycle arrest at the G2 or M phase, whereas treatment with dimethyl malonate (DMM) or oligomycin did not alter cell-cycle status (Extended Data Fig. 1b) . Similar to cells cultured in T H 1 conditions, cells cultured in T H 2 or T H 17 conditions displayed defects in proliferation and an altered cell cycle when treated with rotenone (Extended Data Fig. 2a, b , e, f), which suggests that complex I supports cell division regardless of the cytokine environment.
Further illustrating distinct roles for complex I and complex II in T-helper-cell proliferation and function, we observed that the ATP citrate lysase (ACLY) inhibitor BMS-303141 significantly decreased IFNγ production, consistent with previous work Letter reSeArCH TCA cycle supports T H 1 function by enabling cytosolic acetyl-CoA production and by fuelling a succinate-dehydrogenase (SDH)-driven ETC. This role for the ETC was specific to the T-helper-cell cytokine culture conditions to which the cells were exposed during activation. Unlike T H 1 cells, inhibiting the ETC had a minimal effect on function of T H 2 effector cells; inhibition of complex I or complex III resulted in a slight, but significant, increase in IL-4 reporter activity (Extended Data Fig. 2c ). By contrast, T H 17 cells displayed sensitivity to inhibition of both complex I and complex II (Extended Data Fig. 2d ). These data indicate that the ETC has program-specific roles in regulating the effector functions of T helper cells.
To corroborate the effects of DMM on the function of T H 1 cells, we tested the capacity of three additional inhibitors of complex IIthenoyltrifluoroacetone (TTFA), 3-nitropropionic acid (3NP) and atpenin A5-to inhibit IFNγ production in T H 1 cells. Each drug impaired complex II activity, as assayed by cellular succinate accumulation (Extended Data Fig. 3a) . Consistent with our results for DMM treatment, T H 1 cells treated with 3NP, TTFA or atpenin A5 produced significantly less IFNγ than control cells (Fig. 2a) . In keeping with a role for the TCA cycle and complex II in promoting T H 1 cell function, cells cultured overnight with a membrane-permeable form of succinate (diethyl succinate) produced more IFNγ (Extended Data  Fig. 3b ). To genetically test the requirement of complex II activity in T H 1 cells, we generated a retroviral single-guide (sg)RNA expression vector (which we named MG-Guide) that is compatible with transduction of mouse T cells (Extended Data Fig. 4a, b) . To validate the system, we transduced CD4 T cells with sgRNA and observed a rapid loss of protein expression when using sgRNAs that targeted Tbx21 or Il12rb1, genes that are essential for T H 1-cell cytokine production; this loss led to a decrease in capacity for IFNγ production (Extended Data Fig. 4c-f Fig. 3d, e) . Consistent with our drug and sgRNA studies, Sdhc cKO cells produced significantly less IFNγ at day 5 post-activation (Fig. 2b) . However, Sdhc cKO T H 1 cells proliferated significantly more than wildtype controls, which suggests that proliferation and effector function replicates are presented on summarized plots and unpaired, two-tailed t-test used to determine significance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, not significant. wild type, n = 13; Sdhc cKO, n = 14 biological replicates. Two-tailed t-test. d, Total cellular H3K9 acetylation (H3K9Ac) of wild-type and Sdhc cKO cells cultured in T H 1 conditions at day 3 (n = 3). Two-sided t-test. e, TBET protein expression of wild-type (n = 4) and Sdhc cKO (n = 3) cells cultured in T H 1 conditions at day 5. Two-sided t-test. f, DAVID Gene Ontology (GO) pathway analysis of genes that are downregulated in cKO mice compared to wild-type controls. P < 0.05. g, Heat map of gene expression from RNA-seq results for the cytokine production GO pathway. n, number of technical replicates, except where noted otherwise. Representative plots and a graph summarizing the results of at least two independent experiments are shown, except where noted otherwise. Mean and s.d. of replicates are presented on summarized plots and unpaired, two-tailed t-test used to determine significance. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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are processes that are uncoupled by complex II activity (Fig. 2c ). To test whether processes in addition to proliferation that are involved in T-helper-cell differentiation were affected, we assayed the effect of SDH deficiency on histone acetylation. We found that Sdhc cKO cells exhibited increased H3K9 acetylation, and that DMM treatment as well as delivery of Sdha-targeting sgRNA increased H3K9 and H3K27 acetylation; this suggests that complex II antagonizes T-helper-cell differentiation by negatively regulating both proliferation and histone acetylation ( To test the role of complex II in promoting other aspects of the functional program of T H 1 cells, we evaluated TBET protein expression in Sdhc cKO and wild-type cells on day 5 after activation. Consistent with defects in IFNγ production, T H 1 cells from Sdhc cKO mice had reduced levels of expression of TBET protein (Fig. 2e) . To further investigate a role for complex II in supporting the functional program of T H 1 cells, we performed RNA sequencing (RNA-seq) on effector T H 1 cells from Sdhc cKO and wild-type mice at day 5 after activation. Consistent with a decrease in TBET expression, T H 1 cells from mice deficient in complex II exhibited significantly decreased expression of genes that are key to the T H 1 cell program and genes that are important during T-helper-cell activation. Notably, DAVID (Database for Annotation, Visualization and Integrated Discovery) Gene Ontology pathway analysis indicated 'cytokine production' and 'regulation of lymphocyte proliferation' as the most-dysregulated pathways (Fig. 2f , g, Extended Data Fig. 5d , e, Supplementary Table 2 ). These data indicate that SDH activity is a primary mechanism through which mitochondrial metabolism supports the functional programming of T H 1 cells.
We next sought to investigate which aspects of mitochondrial metabolism are antagonized by SDH to constrain proliferation. The consumption of α-ketoglutarate is known to modulate the activity of mitochondrial shuttling systems that are required to maintain the cellular redox balance and the production of key cytosolic metabolites [9] [10] [11] . The malate-aspartate shuttle and mitochondrial citrate export are two such systems; they regulate the oxidation state of nicotinamide adenine dinucleotides (NAD) in the mitochondria and the transport of acetyl-CoA from the mitochondria to the cytosol, respectively. On the basis of our data that Sdhc cKO T H 1 cells exhibit increased proliferation ( Fig. 2c ) and increased cellular α-ketoglutarate levels (Extended Data Fig. 3e ), we hypothesized that these mitochondrial transport systems promote the early stages of T H 1 cell proliferation.
To test the requirement of these transport systems for T H 1 cell activation, we designed three sgRNAs per gene of interest and conducted individual sgRNA knockout experiments using MG-Guide, measuring IFNγ protein (Fig. 3a) . We found that, compared to cells transduced with an empty MG-Guide vector, cells that express sgRNAs that target Mdh1, Mdh2, Slc25a11 or Slc1a3 produced less IFNγ proteincomparable to the levels observed with sgRNAs that target the positive-control Tbx21 gene-as did two of the three sgRNAs designed to target Got1 and Got2, which suggests that the malate-aspartate shuttle is critical during T H 1 cell activation (Fig. 3b ). In addition, we observed defective IFNγ production in T H 1 cells that express sgRNA against Cs, Slc25a1 and Acly, which indicates that citrate synthesis and export for cytosolic acetyl-CoA production are also required (Fig. 3b) .
Previous reports have suggested that ACLY activity is required for T H 1-cell histone acetylation, and the ETC has previously been shown to support epigenetic remodelling 7, 12 . To test the role of both shuttle systems during T H 1-cell epigenetic remodelling, we evaluated total cellular H3K9 and H3K27 acetylation. We found that impairing Acly, Slc25a1, Mdh1, Slc25a11 and Slc1a3 results in decreased H3K9 acetylation, and that acetate supplementation could compensate for these Letter reSeArCH defects ( Fig. 3c, d ). By contrast, H3K27 acetylation was largely unaffected by targeting these genes (with the exception of Slc25a1); however, the addition of acetate resulted in increased H3K27 acetylation regardless of the condition (Extended Data Fig. 6a ). This effect of acetate on histone acetylation is largely explained by an increase in total H3 content, whereas the effect of the sgRNA on acetylation is only partially explained by changes in total histone mass (Extended Data Fig. 6b-d) .
To evaluate the transcriptional effects of deficiency in the malateaspartate shuttle, we performed RNA-seq at day 5 after activation on T H 1 cells that express sgRNA against Slc25a1 or Slc25a11. Consistent with a role for the shuttles in promoting T H 1 cell differentiation, we observed decreased expression of genes with known roles in T cell activation and T H 1 cell programming. Targeting either of the transporters led to impaired expression of Il2rb, whereas loss of Slc25a1 affected key T-cell-activation genes (such as Nfatc1, Rela and Mapk3) and disruption of Slc25a11 resulted in the loss in expression of genes including Tbx21, Nfatc3, Ccnd2 and Myc (Fig. 3e, f, Extended Data Fig. 6e, f,  Supplementary Tables 3, 4) .
Given the importance of Il2rb, Myc and Ccnd2 in T-helper-cell division, we next evaluated the role of the shuttles in regulating T-helper-cell proliferation. To test this, we evaluated cell division in cells cultured in T H 1 conditions that express sgRNAs targeting Acly, Slc25a1, Mdh1, Slc25a11 or Slc1a3. Relative to controls, targeting any of these genes resulted in modestly-but significantly-decreased proliferation (Extended Data Fig. 7) . Collectively, these data demonstrate that the malate-aspartate shuttle and mitochondrial citrate export are required for T H 1 cell proliferation and transcriptional remodelling.
To investigate the biochemical mechanism that might explain these observations, we performed mass-spectrometry analysis of T cells transduced with guides targeting either Slc25a1 or Slc25a11 sgRNA. As expected, we found that disrupting citrate transport results in decreased levels of cellular acetyl-CoA (Extended Data Fig. 8a-c) . Unexpectedly, targeting Slc25a11 resulted in a decreased cellular NADH/NAD + ratio, which suggests that the activity of complex I is a primary mechanism by which cellular NADH/NAD + is regulated in activated T H 1 cells (Fig. 4a,  Extended Data Fig. 8d, e) . Moreover, targeting either shuttle system resulted in diminished levels of intermediates of the pentose phosphate pathway and of N-carbamoyl-l-aspartate, an essential precursor molecule for nucleotide synthesis (Fig. 4a, Extended Data Figs. 8b, c, 9a, b) . Consistent with a role for the shuttling systems in providing mitochondrial NADH for the ETC, Seahorse analysis demonstrated that rates of basal and maximal oxygen consumption were impaired upon expression of sgRNAs targeting either Mdh1, Slc25a11 or Slc1a3 (Fig. 4b) . This was not substantially compensated for by increased glycolysis, as the extracellular acidification rate was minimally affected (Fig. 4b) .
Having observed that complex I supports early T-helper-cell proliferation and that the malate-aspartate shuttle fuels complex I (Fig. 1c) , we next sought to examine the biochemical mechanism by which complex I promotes proliferation by performing mass-spectrometric analysis on rotenone-treated cells. As expected, inhibiting complex I increased the NADH/NAD + ratio and decreased the ATP/AMP ratio (Fig. 4c,  Extended Data Fig. 9a, b) . Rotenone treatment also led to decreased pools of cellular aspartate and N-carbamoyl-l-aspartate in these cells, similar to previous observations in cancer-cell lines 13, 14 (Fig. 4d) . To test whether this aspartate synthesis deficiency contributed to the proliferative defects of rotenone-treated cells, we supplemented rotenone-treated cells with aspartate and evaluated cell division and the cell cycle. Aspartate supplementation resulted in a significant recovery of cell proliferation, and a partial release from the arrest at the G2 or M phase following rotenone treatment (Fig. 4e, Extended Data Fig. 9c ). These data demonstrate that the regulation of complex I by mitochondrial shuttling systems determines the cellular redox balance and the cytosolic aspartate availability that is required for T cell proliferation.
Using approaches that combine network-level genetic interrogation of metabolic pathways, pharmacology, transcriptomics and metabolomics, we demonstrate how T H 1 cells meet the distinct metabolic demands of differentiation and function during the course of activation. To generate the substrates needed for proliferation and epigenetic remodelling, early activated T helper cells fuel complex I through the malate-aspartate shuttle and mitochondrial citrate export. Unlike the carbon-neutral malate-aspartate shuttle (which exchanges malate for α-ketoglutarate), complex II moves carbon forward in the TCA cycle; this restricts processes that support differentiation and promotes the late-stage effector function of T H 1 cells, which permits cells to exit the . Representative plots and a graph summarizing the results of at least two independent experiments are shown. Mean and s.d. are presented on summarized plots and unpaired, two-sided t-test used to determine significance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
cell cycle and adopt their terminal program (Extended Data Fig. 10 ). These findings illustrate how differentiation and terminal effector function-previously understood to be concordantly regulated by signal transduction-are controlled by distinct metabolic modules, which elucidates how cell programming is governed by parallel transcriptional and biochemical networks.
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Methods
T cell assays and sgRNA delivery. CD4 T cells were isolated from constitutive Cas9-expressing (Cas9tg) B6 mice 15 , stimulated with anti-CD3 and anti-CD28 coated beads (Miltenyi T Cell Activation/Expansion Kit, mouse), and cultured in assay-determined T H 1 conditions (5 ng/ml IL-2, 2 ng/ml IL-12 and 10 μg/ml anti-IL-4). On day 1 post-activation, T cells were transduced with MG-Guide retrovirus using spin transduction at 1,200g for 90 min at 37 °C. IFNγ cytokine was measured by adding brefeldin A, 1 h after the addition of PMA (20 ng/ml) and ionomycin (20 ng/ml); 4 h after restimulation, cells were fixed, stained with anti-CD4 (Biolegend), anti-GFP (Millipore) and anti-IFNγ (Biolegend), and analysed by flow cytometry. To assay for Ifng-Katushka, IL-4-GFP, and IL-17-GFP expression, T cells from Ifng-Katushka 16 , 4GET (Jackson Labs, 004190) and IL-17-GFP (Jackson Labs, 018472) reporter mice were activated with PMA and ionomycin for four hours, stained with anti-CD4 and then analysed by flow cytometry for reporter activity in GFP + cells. Cell division was measured by labelling cells with CellTrace Violet (Thermo) before activation, and evaluated for proliferation at day 3 after activation; where indicated, inhibitors and metabolites were added to the medium overnight on day 2 after activation. Cell-cycle status was determined by intracellular flow cytometry analysis of Ki67 and DAPI, at day 3 after activation; where indicated, inhibitors and metabolites were added to the medium overnight on day 2 after activation. Mitochondrial reactive oxygen species was measured by flow cytometry in CD4 T cells by staining cells with MitoSOX Red mitochondrial superoxide indicator (Thermo) and anti-CD4 for 30 min at 37 °C in the presence of the indicated inhibitors. For all experiments using inhibitors or metabolite supplementation, the following doses were used: 1 μM rotenone (Sigma), 10 mM DMM (Sigma), 1 mM 3NP (Sigma), 100 μM TTFA (Sigma), 1 μM atpenin A5 (Cayman Chemical), 1 μM antimycin A (Sigma), 1 μM oligomycin (Sigma), 5mM diethyl succinate (Sigma) or 20mM aspartate. All mice required for this study were housed and maintained under specific-pathogen-free conditions in the animal facility of the Yale University School of Medicine, and all corresponding animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Yale University. This study was conducted in compliance with all relevant ethical regulations. All cells used for experimentation were collected from male and female mice at 6-8 weeks of age. MG-Guide vector generation, sgRNA cloning and retroviral production. MG-Guide was generated by removing the IRES element from MIGR1 (Addgene) by EcoRI and NotI digestion, and adding the human U6 promoter and SV40 promoter from pMKO-GFP (Addgene) by infusion assembly (Clonetech). To add the sgRNA cloning site, the vector was digested with AgeI and EcoRI and combined by infusion assembly with an IDT Gene Block containing two BbsI restriction sites upstream of a scaffold RNA sequence and a U6 stop. To clone individual sgRNAs, MG-Guide was digested with BbsI and pairs of oligonucleotides (Sigma) with complimentary overhangs were annealed and ligated into the vector. For retroviral production, 1 μg of MG-Guide plasmid and 0.5 μg of EcoHelper plasmid were transfected into 5 × 10 5 HEK293T cells (source ATCC, identity unconfirmed, not tested for mycoplasma) in a 6-well plate using X-tremeGENE 9 DNA Transfection Reagent (Roche) overnight. The medium was then replaced, and virus was collected 24 h later. Isolated CD4 T cells (1 × 10 6 ) were stimulated overnight, and spin-transduced in the viral preparation with 1 μg/ml polybrene at 1,200g for 90 min at 37 °C. RNA-seq analysis. Raw reads from RNA-seq were aligned to the mouse genome mm10 with STAR 2.7.0 17 , and gene-expression levels were measured by HTSeq 0.11.1 18 . Subsequently, differential expression analysis between different groups was performed with DESeq2 19 . Seahorse analysis. Analysis was performed on cells at day 3, day 4 and day 5 after activation. Cells were washed three times in complete Seahorse medium (Seahorse Bioscience) with 10 mM glucose, 1 mM sodium pyruvate and 2 mM glutamine. Cells were plated at 4 × 10 4 cells per well in a 96-well Seahorse assay plate, pretreated with poly-d-lysine. Cells were equilibrated to 37 °C for 30 min before assay. OCR (pmoles/min) and ECAR (mpH/min) were measured as indicated upon cell treatment with oligomycin (0.5 mM), FCCP (0.2 mM), rotenone (1 μM), DMM (10 mM) and antimycin A (1 μM), according to the manufacturer's instructions. Metabolome extraction. Cells were seeded at 1 × 10 6 cells/ml and incubated for 4 h in complete RPMI containing dialysed FBS medium. Cells were then transferred to 1.5-ml tubes and pelleted (1 min, 6,000g, at room temperature). Medium was removed by aspiration and the cells were washed once with 500 μl of PBS. Metabolome extraction was performed by the addition of 50 μl of ice cold solvent (40:40:20 acetonitrile:methanol:water + 0.5% formic acid). After a 5-min incubation on ice, acid was neutralized by the addition of NH 4 HCO 3 . After centrifugation (15 min, 16 ,000g, at 4 °C), the clean supernatant was transferred to a clean tube, frozen on dry ice and kept at -80 °C until liquid chromatography-mass spectrometry (LC-MS) analysis 20 . Succinate quantification. Wild-type CD4 T cells (1 × 10 6 ) were activated under T H 1 culture conditions. After 4 days, cells were replated into fresh medium and cultured with DMSO, 10 mM DMM, 1 mM 3NP, 100 μM TTFA or 1 μM atpenin A5 for 6 h. Cells were then collected, processed and analysed using the Succinate Assay Kit (Abcam) according to the manufacturer's protocol. LC-MS analysis. Cell extracts were analysed using a quadrupole-orbitrap mass spectrometer (Q Exactive, Thermo Fisher Scientific) coupled to hydrophilic interaction chromatography via electrospray ionization. Liquid chromatography separation was on a XBridge BEH Amide column (2.1 mm × 150 mm, 2.5-μm particle size; Waters) using a gradient of solvent A (20 mM ammonium acetate, 20 mM ammonium hydroxide in 95:5 water:acetonitrile, pH 9.45) and solvent B (acetonitrile). Flow rate was 150 μl/min, column temperature was 25 °C, autosampler temperature was 5 °C and injection volume was 10 μl. The liquid chromatography gradient was: 0 min, 90% B; 2 min, 85% B; 3 min, 75% B; 7 min, 75% B; 8 min, 70% B; 9 min, 70% B; 10 min, 50% B; 12 min, 50% B; 13 min, 25% B; 14 min, 25% B; 16 min, 0% B; 21 min, 0% B; 22 min, 90% B; 25 min, 90% B. Autosampler temperature was 5 °C and injection volume was 10 μl. The mass spectrometer was operated in negative-ion mode to scan from m/z 70 to 1,000 at 1 Hz and a resolving power of 140,000 21 . Data were analysed using the MAVEN software 22 . Statistical analysis. Experiments were conducted with technical and biological replicates at an appropriate sample size, as estimated by our prior experience. No statistical methods were used to predetermine sample size. No methods of randomization and no blinding were applied. All data were replicated independently at least once as indicated in the figure legends, and all attempts to reproduce experimental data were successful. For all bar graphs, mean + s.d. are shown. All statistical analysis was performed using GraphPad Prism 7 (or more recent versions). P values < 0.05 were considered significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; P values > 0.05 were considered as non-significant. FlowJo 8.0 (or more recent versions) (Treestar) was used to analyse flow cytometry data. All sample sizes and statistical tests used are detailed in each figure legend. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. = 3) . n, number of technical replicates. Representative plots and a graph summarizing the results of three independent experiments are shown. Mean and s.d. of replicates are presented on summarized plots and unpaired, two-tailed t-test used to determine significance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Fig. 3 | Complex II inhibition is functional and leads to a loss of IFNγ production in T H 1 cells. a, Cellular succinate at day 5 evaluated using Succinate Assay Kit (Abcam) in wild-type CD4 T cells cultured in T H 1 conditions following 6-h treatment with DMSO, 10 mM DMM, 1 mM 3NP, 100 μM TTFA or 1 μM atpenin A5 (n = 3). b, IFNγ protein production after PMA and ionomycin restimulation at day 5 of wild-type CD4 T cells cultured in T H 1 conditions following 16-h overnight treatment with 10 mM diethyl succinate (DES) (n = 5) or DMSO (n = 4). c, IFNγ protein production after PMA and ionomycin restimulation at day 5 of Cas9-expressing CD4 T cells cultured in T H 1 conditions transduced with one of three individual sgRNA targeting Sdha, or an empty-vector control (n = 3 biological replicates). d, e, Total cellular succinate (d) and α-ketoglutarate (e) measured by LC-MS analysis in wild-type or Sdhc cKO CD4 T cells cultured in T H 1 conditions after 4-h culture in dialysed FBScontaining medium at day 5 (n = 3). n, number of technical replicates, unless otherwise stated. Representative plots and a graph summarizing the results of at least two independent experiments are shown. Mean and s.d. of replicates are presented on summarized plots and unpaired, two-tailed t-test used to determine significance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Fig. 4 | Retroviral expression of sgRNA in Cas9-expressing CD4 T cells. a, Schematic of MG-Guide retroviral vector. b, CD4 T cells from Cas9-expressing mice were stimulated with anti-CD3 and anti-CD28 coated beads for 24 h and retrovirally transduced with either a MG-Guide (empty vector) or a MG-Guide vector cloned to express a sgRNA against Thy1 (Thy1 sgRNA). GFP expression was measured at 24 h after transduction, compared to non-transduced cells. c, THY1.1 protein expression was measured in transduced (empty vector blue line; Thy1 sgRNA red line) and non-transduced (solid grey) cells by flow cytometry at 30 and 96 h after transduction. d, Schematic of experimental design for functional T H 1 sgRNA studies. e, CD4 T cells from Cas9-expressing mice were stimulated with anti-CD3 and anti-CD28 beads in IL-2 (5 ng ml −1 ), anti-IL-4 (10 μg ml −1 ) and IL-12 (2 ng ml −1 ) and retrovirally transduced 24 h after activation with either empty MG-Guide (shaded blue) or MG-Guide expressing a sgRNA against Tbx21 (outline). TBET protein expression was measured by intracellular flow cytometry on day 3. f, Cas9-expressing CD4 T cells were cultured as above, and infected with MG-Guide, a sgRNA against Tbx21 or a sgRNA against Il12rb. IFNγ protein was measured by intracellular flow cytometry on day 5 after restimulation with PMA (20 ng ml −1 ) and ionomycin (1 μg ml −1 ). . n, number of technical replicates. Representative plots and a graph summarizing the results of at least two independent experiments are shown. Mean and s.d. of replicates are presented on summarized plots and unpaired, two-tailed t-test used to determine significance. **P < 0.01, ****P < 0.0001.
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Extended Data Fig. 10 | Conceptual models of mitochondrial metabolite transport and the consequence of metabolic perturbations on T H 1 cell activation. a, Early-stage T H 1 cell activation is supported by the malate-aspartate shuttle and mitochondrial citrate export. These mitochondrial transport systems provide the key substrates that are needed for cell division and histone acetylation. Citrate export results in the production of cytosolic acetyl-CoA that can be used to synthesize the fatty acids that are needed for plasma membrane expansion during division, as well as the acetyl groups that are used for histone acetylation. Interconnected with this export pathway is the malate-aspartate shuttle, a carbon-neutral cycle that results in the net movement of NAD + to the cytosol and NADH into the mitochondria, through which the cycle can fuel the activity of ETC complex I. Through the activity of complex I, NAD + can be continually recycled, which enables the production of aspartate (an essential precursor for nucleotide synthesis). These processes are antagonized by the activity of SDH (ETC complex II), which consumes α-ketoglutarate; this limits the availability of the latter for the malate-aspartate shuttle and promotes effector functions of T H 1 cells. b, T-helper-cell activation is defined by two major phases: (1) a period of rapid division and epigenetic remodelling, and (2) cell-cycle arrest and cytokine production. Each of these phases is supported by a discrete component of mitochondrial metabolism. The malate-aspartate shuttle and mitochondrial citrate export generate the material needed for earlyphase cell differentiation to occur. As differentiation continues, the activity of complex II draws carbon away from the shuttle, and thus acts to pull activated T H 1 cells out of the differentiation process and to enable them to fully engage their terminal effector cell program. When the mitochondrial transport networks are disrupted, T H 1 cells are unable to properly proliferate or epigenetically reprogram. By contrast, inhibiting the activity of complex II causes activated T H 1 cells to continuously proliferate and remodel their chromatin, which prevents them from exiting the differentiation phase and engaging their terminal effector program. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
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For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
For flow cytometry software information, please see the flow cytometry form. All graphing and associated statistical analysis was performed using GraphPad Prism 7 or newer. MAVEN (build 682) was used for LC-MS analysis (http://genomics-pubs.princeton.edu/mzroll/index.php). STAR 2.7.0 was used for alignment of RNA-seq data. HTseq 0.11.1 was used for gene expression. DEseq2 was used for differential expression.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request. RNA-seq data sets have been deposited in Gene Expression Omnibus under the accession number GSE130713 Ethics oversight
All mice required for this study were housed and maintained under specific-pathogen-free conditions in the animal facility of the Yale University School of Medicine, and all corresponding animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Yale University. This study was conducted in compliance with all relevant ethical regulations.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Cells were harvested, washed at least once with PBS, and stained with antibodies targeting surface antigens in 2%FBS 1mM EDTA in PBS for 30 minutes on ice. For analysis of intracellular cytokine staining, cells were then fixed and permeabilized with fixation/ permeabilization solution (BD Cytofix/Cytoperm Cat#554714) at 4C for 20 minutes. For nuclear transcription factor staining, cells were fixed and permeabilized with eBioscience Foxp3/Transcription Factor Fixation/Permeabilization Concentrate and Diluent (Cat #00-5521-00). Cells were then washed three times with 1X permeabilization buffer (eBioscience Permeabilization Buffer Cat #00-8333-56) and stained for intracellular antigens for 1 hour on ice in 1X permeabilization buffer. Cells were then washed two times before proceeding to cytometry analysis. For cells not transduced with retrovirus, cells were labeled with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (ThermoFisher Cat# L34965) per the manufactures protocol before surface staining. Further details regarding specific staining protocols and antibodies used can be found in the methods section of the manuscript. Cells were harvested, washed at least once with PBS, and stained with antibodies targeting surface antigens in 2%FBS 1mM EDTA in PBS for 30 minutes on ice. For analysis of intracellular cytokine staining, cells were then fixed and permeabilized with fixation/ permeabilization solution (BD Cytofix/Cytoperm Cat#554714) at 4C for 20 minutes. For nuclear transcription factor staining, cells were fixed and permeabilized with eBioscience Foxp3/Transcription Factor Fixation/Permeabilization Concentrate and Diluent (Cat #00-5521-00). Cells were then washed three times with 1X permeabilization buffer (eBioscience Permeabilization Buffer Cat #00-8333-56) and stained for intracellular antigens for 1 hour on ice in 1X permeabilization buffer. Cells were then washed two times before proceeding to cytometry analysis. For cells not transduced with retrovirus, cells were labeled with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (ThermoFisher Cat# L34965) per the manufactures protocol before surface staining. Further details regarding specific staining protocols and antibodies used can be found in the methods section of the manuscript.
Instrument
BD LSRII custom order product Software BD FACSDiva Software was used to collect raw data files from all flow cytometry experiments. All resultant data files were analyzed using FlowJo version 8 or newer.
Cell population abundance Cells were purified for three replicate screens using a BD FACS Aria as described in methods. Due to limited cell numbers, all resultant cells were processed for gDNA isolation and sequencing.
